SMMT Q4 2024 Earnings — Summit Therapeutics Inc. Revenue & Financial Results | Market Cap Arena

SMMTSummit Therapeutics Inc.

$12B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$15M

Operating Income

-$66M

Net Income

-$61M

EPS (Diluted)

$-0.08

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$49M

Free Cash Flow

-$49M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$436M

Total Liabilities

$47M

Stockholders' Equity

$389M

Cash & Equivalents

$105M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$15M	-$840,000	-1678.6%
Operating Income	-$66M	-$28M	-131.0%
Net Income	-$61M	-$29M	-113.4%